SUFENTANIL CITRATE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Selective mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
| Metabolism | Primarily hepatic via N-dealkylation and O-demethylation mediated by CYP3A4; metabolites are mostly inactive; undergoes extensive first-pass metabolism. |
| Excretion | Renal (metabolites, <1% unchanged); fecal (biliary elimination of metabolites); approximately 80% renal, 20% fecal. |
| Half-life | Terminal elimination half-life: 2-4 hours (adults), 1-3 hours (neonates), 3-6 hours (elderly). Context: context-sensitive half-time increases with infusion duration. |
| Protein binding | Approximately 92.5% bound; primarily to alpha-1-acid glycoprotein and albumin. |
| Volume of Distribution | Steady-state Vd: 1.5-3.0 L/kg; large Vd indicates extensive tissue distribution. |
| Bioavailability | Intravenous: 100%; epidural: approximately 90%; intrathecal: approximately 100% (relative to IV); oral: negligible due to first-pass metabolism. |
| Onset of Action | Intravenous: 1-3 minutes; epidural: 5-10 minutes; intrathecal: 5-15 minutes. |
| Duration of Action | Intravenous: 20-30 minutes (analgesic effect, dose-dependent); epidural: 1-4 hours (dose-dependent); context: redistribution limits duration, higher doses prolong effect. |
0.5-5 mcg/kg IV/IM for induction of anesthesia; 0.1-0.3 mcg/kg IV for epidural analgesia; 0.3-0.8 mcg/kg IV for short operative procedures; maintenance with 0.1-0.3 mcg/kg IV every 1-2 hours as needed.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate impairment (eGFR ≥30 mL/min/1.73m²). For severe impairment (eGFR <30 mL/min/1.73m²), consider reducing dose and titrating cautiously due to potential accumulation of metabolites. |
| Liver impairment | For Child-Pugh Class B: reduce dose by 25-50%. For Child-Pugh Class C: avoid use or reduce dose by 50% with careful monitoring. |
| Pediatric use | Neonates: 0.5-1 mcg/kg IV for minor procedures; Children 1-12 years: 0.5-2 mcg/kg IV for induction; maintenance 0.1-0.3 mcg/kg IV every 1-2 hours. Titrate based on response. |
| Geriatric use | Reduce initial dose by 50% (e.g., 0.25-2.5 mcg/kg IV) and titrate slowly due to increased sensitivity and prolonged half-life. Consider lower infusion rates. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants including alcohol and benzodiazepines increase sedation risk Life-threatening respiratory depression may occur.
| Breastfeeding | Excreted in human milk. The M/P ratio is unknown. Use with caution; monitor infant for signs of respiratory depression and sedation. Consider risk of neonatal opioid withdrawal if used chronically. Alternative analgesics are preferred during breastfeeding. |
| Teratogenic Risk | Sufentanil citrate is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but no adequate human studies exist. First trimester: Potential for teratogenic effects based on animal data; use only if benefit outweighs risk. Second and third trimesters: Risk of fetal respiratory depression and maternal opioid withdrawal if used chronically. Use near term may cause neonatal opioid withdrawal syndrome. |
■ FDA Black Box Warning
Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of interactions with CNS depressants including alcohol; risk of hypotension and bradycardia in patients with compromised cardiovascular function.
| Common Effects | analgesia |
| Serious Effects |
Hypersensitivity to sufentanil or any component of the formulation; acute or severe bronchial asthma; upper airway obstruction; known or suspected paralytic ileus; concurrent use with MAOIs or within 14 days of discontinuation.
| Precautions | Monitor respiratory function closely; use with caution in patients with head injury, increased intracranial pressure, or respiratory conditions; may cause muscle rigidity, especially with rapid IV administration; avoid abrupt discontinuation after prolonged use; use with caution in patients with hepatic or renal impairment; concomitant use with other CNS depressants increases risk of adverse effects. |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory rate, oxygen saturation, heart rate, blood pressure, and sedation level. Fetal heart rate monitoring is recommended during prolonged use or near term. Observe neonate for respiratory depression, hypotonia, and withdrawal symptoms. |
| Fertility Effects | Sufentanil may impair male and female fertility based on animal studies. In humans, chronic opioid use can lead to hypogonadism, menstrual irregularities, and reduced libido. Acute use has unclear effects on fertility. |